A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs CX 8998 (Primary)
- Indications Arrhythmias; Essential tremor
- Focus Proof of concept; Therapeutic Use
- Acronyms T-CALM Sudy
- Sponsors Cavion
- 19 Apr 2018 According to a Cavion media release, data from this study will be preasented at 70th American Academy of Neurology (AAN) Annual Meeting
- 05 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 05 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.